Andreas Du Bois - Gynecology

Author Information

Dr. Andreas Du Bois is a distinguished researcher in the field of Gynecology and Gynecologic Oncology. He is currently affiliated with the Department of Gynecology and Gynecologic Oncology at Evangelische Kliniken Essen-Mitte in Essen, Germany. His extensive work primarily focuses on ovarian cancer, including advanced and relapsed cases, and he has made significant contributions to understanding and treating this disease.

Research Contributions

Dr. Du Bois has made substantial contributions to gynecologic oncology, particularly in the context of ovarian cancer. His research spans various critical areas, including disease cure probabilities before the PARP inhibitor era, genomic instability, homologous recombination deficiency testing, and the use of cell-free tumor DNA for assessing tumor burden. He has also investigated polygenic risk modeling and has published findings from randomized trials on cytoreductive surgery for relapsed ovarian cancer. His work is highly regarded and has been featured in numerous reputable journals.

Aliases

Andrea Du Bois, A Du Bois, A. A Du Bois, A. Du Bois, Andreas Du Bois

Publication and Citation Metrics

Metric	Value
Citation Count	23,083
h-index	65
Paper Count	426

Publications:

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.

DOI: 10.1038/s41416-022-01732-7

Year: 2022

Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation

DOI: 10.1136/ijgc-2022-003397

Year: 2022

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial

DOI: 10.3390/cancers14051189

Year: 2022

Homologous recombination deficiency testing in first-line ovarian cancer.

DOI: 10.1016/j.annonc.2021.12.013

Year: 2022

Cytoreductive Surgery for Relapsed Ovarian Cancer. Reply.

DOI: 10.1056/NEJMc2120128

Year: 2022

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer

DOI: 10.1371/journal.pone.0262770

Year: 2022

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

DOI: 10.1038/s41431-022-01085-y

Year: 2022

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

DOI: 10.1097/01.ogx.0000824536.49876.91

Year: 2022

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

DOI: 10.1038/s41431-021-00987-7

Year: 2022

Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome.

DOI: 10.1136/ijgc-2021-003173

Year: 2022

What is Natural Orifice Transluminal Endoscopic Surgery (NOTES)?

What is Cat-Cow Pose?

Who Can Have an Abortion?

Can AMH Levels Predict Fertility?

What Should I Expect After the Procedure?

What is Glucocorticoid Induced Osteoporosis?

What Types of Follow-Up Tests are Common?

What are the Symptoms of Low Total Testosterone Levels?

What Conditions Can Be Treated with Electrical Stimulation?

What Constitutes a Normal Menstrual Cycle?

Partnered Content Networks

Relevant Topics